# A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

> **NCT05127434** · PHASE2,PHASE3 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 36814 (actual)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **DRUG:** Placebo
- **DRUG:** mRNA-1345

## Key facts

- **NCT ID:** NCT05127434
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-17
- **Primary completion:** 2025-07-28
- **Final completion:** 2025-07-28
- **Target enrollment:** 36814 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05127434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05127434, "A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05127434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*